These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 667870)

  • 1. QRS voltage change with adriamycin administration.
    Minow RA; Benjamin RS; Lee ET; Gottlieb JA
    Cancer Treat Rep; 1978 Jun; 62(6):931-4. PubMed ID: 667870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases].
    Wang SQ
    Zhonghua Zhong Liu Za Zhi; 1991 Jan; 13(1):71-3. PubMed ID: 1889343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adriamycin cardiomyopathy--risk factors.
    Minow RA; Benjamin RS; Lee ET; Gottlieb JA
    Cancer; 1977 Apr; 39(4):1397-402. PubMed ID: 856438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Noninvasive cardia fĂșnction diagnosis in children treated with adriamycin (author's transl)].
    Schmaltz AA; Treuner J; Class U; Heil RP
    Klin Padiatr; 1980 Nov; 192(6):502-8. PubMed ID: 7194391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity.
    Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ
    Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrocardiographic changes after adriamycin chemotherapy.
    Ali MK; Soto A; Maroongroge D; Bekheit-Saad S; Buzdar AU; Blumenschein GR; Hortobagyi GN; Tashima CK; Wiseman CL; Shullenberger CC
    Cancer; 1979 Feb; 43(2):465-71. PubMed ID: 421174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial studies of cardiac function in patients receiving adriamycin.
    Henderson IC; Sloss LJ; Jaffe N; Blum RH; Frei E
    Cancer Treat Rep; 1978 Jun; 62(6):923-9. PubMed ID: 667869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.
    Chlebowski RT; Paroly WS; Pugh RP; Hueser J; Jacobs EM; Pajak TF; Bateman JR
    Cancer Treat Rep; 1980 Jan; 64(1):47-51. PubMed ID: 7379058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin].
    Okuma K; Furuta I; Ota K
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):502-8. PubMed ID: 6703724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiomyopathy due to adriamycin: the possibility of its prevention. Monitoring by noninvasive technics].
    Bianchi L; Bertocchi C; Felci U; Ferrario G; Giani P; Mariani L; Medolago G; Sarti E
    Minerva Med; 1989 Mar; 80(3):215-26. PubMed ID: 2717043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiotoxicity due to prolonged administration of THP (2"R-4'-O-tetrahydropyranyl-adriamycin)].
    Suzuki M; Hirono M; Majima H
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1993-9. PubMed ID: 9350248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for doxorubicin-induced congestive heart failure.
    Von Hoff DD; Layard MW; Basa P; Davis HL; Von Hoff AL; Rozencweig M; Muggia FM
    Ann Intern Med; 1979 Nov; 91(5):710-7. PubMed ID: 496103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of electrocardiographic QRS width in patients with congestive heart failure: a marker for biventricular pacing].
    Igarashi M; Shiina Y; Tanabe T; Handa S
    J Cardiol; 2002 Sep; 40(3):103-9. PubMed ID: 12325459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adriamycin and mitomycin C: possible synergistic cardiotoxicity.
    Buzdar AU; Legha SS; Tashima CK; Hortobagyi GN; Yap HY; Krutchik AN; Luna MA; Blumenschein GR
    Cancer Treat Rep; 1978 Jul; 62(7):1005-8. PubMed ID: 688243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total 12-Lead QRS Voltage in Patients Having Orthotopic Heart Transplantation for Heart Failure Caused by Adriamycin-Induced Cardiomyopathy.
    Roberts WC; Haque S; Hall SA
    Cardiology; 2018; 141(3):172-175. PubMed ID: 30650419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible doxorubicin-induced congestive heart failure.
    Cohen M; Kronzon I; Lebowitz A
    Arch Intern Med; 1982 Aug; 142(8):1570-1. PubMed ID: 7103641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats.
    Mettler FP; Young DM; Ward JM
    Cancer Res; 1977 Aug; 37(8 Pt 1):2705-13. PubMed ID: 872096
    [No Abstract]   [Full Text] [Related]  

  • 18. [Is the use of adriamycin (doxorubicin) limited by its cardiotoxicity?].
    Reinhardt D; Hofmann V; Martz G
    Schweiz Med Wochenschr; 1985 Apr; 115(16):557-61. PubMed ID: 4001904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature.
    Lieverse RJ; Ossenkoppele GJ
    Neth J Med; 1991 Feb; 38(1-2):33-4. PubMed ID: 2030807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.